Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines
Competition Results In Few Monopolies Lasting Until Patent Expiry
Executive Summary
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.